High levels of global hydroxymethylation predict worse overall survival in MDS patients treated with azacitidine.
Saved in:
| Title: | High levels of global hydroxymethylation predict worse overall survival in MDS patients treated with azacitidine. |
|---|---|
| Authors: | Tiso F; Department of Laboratory Medicine, Laboratory of Hematology Radboud University Medical Center and Radboud Institute for Molecular Life Sciences Nijmegen The Netherlands., In 't Hout FEM; Department of Laboratory Medicine, Laboratory of Hematology Radboud University Medical Center and Radboud Institute for Molecular Life Sciences Nijmegen The Netherlands.; Department of Hematology Radboud University Medical Center Nijmegen The Netherlands., Knops R; Department of Laboratory Medicine, Laboratory of Hematology Radboud University Medical Center and Radboud Institute for Molecular Life Sciences Nijmegen The Netherlands., Kroeze LI; Department of Pathology Radboud University Medical Center Nijmegen The Netherlands., van Rooij A; Department of Laboratory Medicine, Laboratory for Genetic, Endocrine, and Metabolic Diseases Radboud University Medical Center Nijmegen The Netherlands., van de Loosdrecht AA; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands., Westers TM; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands., Langemeijer SMC; Department of Hematology Radboud University Medical Center Nijmegen The Netherlands., Preudhomme C; Department Hematology Lille University Hospital Lille and INSERM UMR-S 1277 Lille France., Duployez N; Department Hematology Lille University Hospital Lille and INSERM UMR-S 1277 Lille France., Fenaux P; Department Hematology Hôpital Saint Louis, Assistance publique hôpitaux de paris, and Université de Paris Cité Paris France., Kosmider O; Division INSERM U1016, Assistance Publique-Hôpitaux de Paris, Cochin Hospital and Université Paris Cité, CNRS, INSERM Cochin Institute Paris France., Bouscary D; Division INSERM U1016, Assistance Publique-Hôpitaux de Paris, Cochin Hospital and Université Paris Cité, CNRS, INSERM Cochin Institute Paris France., de Graaf AO; Department of Laboratory Medicine, Laboratory of Hematology Radboud University Medical Center and Radboud Institute for Molecular Life Sciences Nijmegen The Netherlands., Martens JHA; Department of Molecular Biology Radboud University Nijmegen The Netherlands., van der Reijden BA; Department of Laboratory Medicine, Laboratory of Hematology Radboud University Medical Center and Radboud Institute for Molecular Life Sciences Nijmegen The Netherlands., Adès L; Department Hematology Hôpital Saint Louis, Assistance publique hôpitaux de paris, and Université de Paris Cité Paris France., Fontenay M; Division INSERM U1016, Assistance Publique-Hôpitaux de Paris, Cochin Hospital and Université Paris Cité, CNRS, INSERM Cochin Institute Paris France., Jansen JH; Department of Laboratory Medicine, Laboratory of Hematology Radboud University Medical Center and Radboud Institute for Molecular Life Sciences Nijmegen The Netherlands. |
| Source: | HemaSphere [Hemasphere] 2025 Jan 03; Vol. 9 (1), pp. e70034. Date of Electronic Publication: 2025 Jan 03 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
